BioSyent, Inc. (RX.V)
15.50
-0.20
(-1.27%)
CAD |
TSXV |
Aug 24, 16:00
BioSyent Enterprise Value : 169.97M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 169.97M |
| August 21, 2026 | 172.24M |
| August 20, 2026 | 161.47M |
| August 19, 2026 | 161.47M |
| August 18, 2026 | 159.77M |
| August 17, 2026 | 159.77M |
| August 14, 2026 | 167.14M |
| August 13, 2026 | 164.42M |
| August 12, 2026 | 162.03M |
| August 11, 2026 | 164.30M |
| August 10, 2026 | 164.30M |
| August 07, 2026 | 164.30M |
| August 06, 2026 | 169.86M |
| August 05, 2026 | 169.97M |
| August 04, 2026 | 160.33M |
| July 31, 2026 | 161.47M |
| July 30, 2026 | 160.45M |
| July 29, 2026 | 160.45M |
| July 28, 2026 | 161.47M |
| July 27, 2026 | 161.35M |
| July 24, 2026 | 161.35M |
| July 23, 2026 | 160.79M |
| July 21, 2026 | 160.90M |
| July 20, 2026 | 158.63M |
| July 17, 2026 | 158.63M |
| Date | Value |
|---|---|
| July 16, 2026 | 158.63M |
| July 15, 2026 | 159.77M |
| July 14, 2026 | 159.77M |
| July 13, 2026 | 159.65M |
| July 10, 2026 | 159.77M |
| July 09, 2026 | 161.13M |
| July 08, 2026 | 160.22M |
| July 07, 2026 | 157.72M |
| July 06, 2026 | 159.43M |
| July 03, 2026 | 158.63M |
| July 02, 2026 | 157.95M |
| June 30, 2026 | 158.63M |
| June 29, 2026 | 164.95M |
| June 26, 2026 | 157.52M |
| June 25, 2026 | 156.13M |
| June 24, 2026 | 156.94M |
| June 23, 2026 | 157.40M |
| June 22, 2026 | 156.94M |
| June 19, 2026 | 156.36M |
| June 18, 2026 | 156.36M |
| June 17, 2026 | 155.31M |
| June 16, 2026 | 156.94M |
| June 15, 2026 | 156.36M |
| June 12, 2026 | 155.66M |
| June 11, 2026 | 156.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| HLS Therapeutics, Inc. | 155.36M |
| Bausch Health Cos., Inc. | 31.70B |
| Cipher Pharmaceuticals, Inc. | 345.95M |
| Revive Therapeutics Ltd. | 10.94M |
| Knight Therapeutics, Inc. | 873.52M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.849M |
| Revenue (Quarterly) | 19.87M |
| Total Expenses (Quarterly) | 17.02M |
| EPS Diluted (Quarterly) | 0.245 |
| Gross Profit Margin (Quarterly) | 65.02% |
| Profit Margin (Quarterly) | 14.34% |
| Earnings Yield | 5.53% |
| Operating Earnings Yield | 7.24% |
| Normalized Earnings Yield | 5.530 |